The mineralocorticoid receptor (MR), a member of the steroid receptor family, acts as a transcription factor and mediates both aldosterone and cortisol effects. Aldosterone specificity in some tissues results from the inactivation of competing cortisol into cortisone by 11beta-hydroxysteroid dehydrogenase. In other tissues MR and the glucocorticoid receptor show overlapping physiological effects or may act together by forming a heterodimer. An additional MR splice variant (MR+4) has been found in different mRNA samples from rat tissues and human white blood cells, thereby implying additional modes of MR-regulated effects. We therefore looked for the presence of these two MR-mRNA isoforms in human classical aldosterone target tissues and various other tissues. MR-mRNA was found in all samples investigated, thereby showing the expression of MR to be more abundant than has been observed thus far. In addition, the MR+4-mRNA variant was also found in all the tissues examined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1530/eje.0.1380702 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Do Potassium Binders Block Both the Benefits and the Risks of Mineralocorticoid Receptor Antagonists in Heart Failure?: The Four Anti-Aldosterone Myths.
J Am Coll Cardiol
March 2025
Baylor Heart and Vascular Institute, Dallas, Texas, USA; Imperial College, London, United Kingdom. Electronic address:
Finerenone Alleviates Over-Activation of Complement C5a-C5aR1 Axis of Macrophages by Regulating G Protein Subunit Alpha i2 to Improve Diabetic Nephropathy.
Cells
February 2025
Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China.
Diabetic nephropathy (DN), one of the most common complications of diabetes mellitus (DM), accounts for a major cause of chronic kidney disease (CKD) worldwide, with a complicated pathogenesis and limited effective strategies nowadays. The mineralocorticoid receptor (MR) is a classical ligand-activated nuclear transcription factor. It is expressed in the renal intrinsic and immune cells, especially macrophages.
View Article and Find Full Text PDFNovel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial.
JMIR Res Protoc
March 2025
Department of Cardiology, Life Bay View Private Hospital, Mossel Bay, South Africa.
Background: Chronic heart failure has high morbidity and mortality, with approximately half of the patients dying within 5 years of diagnosis. Recent additions to the armamentarium of anti-heart failure therapies include angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium/glucose cotransporter 2 inhibitors (SGLT2is). Both classes have demonstrated mortality and morbidity benefits.
View Article and Find Full Text PDFBackground: New postoperative atrial fibrillation (POAF) occurs in about 40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We examined the impact of preoperative MRA use on POAF and also examine the atrial cell type impacted by MRA treatment during cold cardiac preservation.
View Article and Find Full Text PDFThe COVID-19 Pandemic Did Not Negatively Impact Adherence to Cardiovascular Medications Among 548,601 Chronically Treated Patients in Alberta.
CJC Open
February 2025
Canadian Vigour Centre, Katz Group Centre for Pharmacy and Health Research, University of Alberta College of Health Sciences, Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada.
Background: Studies have suggested that the COVID-19 pandemic negatively impacted patient adherence with chronic medications. We explored whether adherence patterns changed in patients chronically treated with cardiovascular drugs after onset of the COVID-19 pandemic.
Methods: In this retrospective cohort study we examined drug dispensation data for all adult Albertans who were chronic users of at least 1 cardiovascular drug class between 2017 and 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!